Status:
TERMINATED
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Lead Sponsor:
Nevada Cancer Institute
Conditions:
Non-Small Cell Lung Cancer and Pleural Mesothelioma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2). This study is designed ...
Detailed Description
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2). This study is designed ...
Eligibility Criteria
Inclusion
- Patients with advanced non-small cell lung cancers (non-squamous variety and advanced mesotheliomas
- Patients with advanced solid tumors who are refractory to standard treatments and/or standard treatments are not be available for the patient
Exclusion
- Non-small cell carcinoma of squamous variety
- Patients with uncontrolled brain metastases
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
August 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00281125
Start Date
January 1 2006
End Date
August 1 2008
Last Update
March 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89135